Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$9.48B
Positions
135
New
8
Increased
31
Decreased
7
Sold Out
8
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $9.48B across 135 positions in their Q1 2016 SEC 13F filing (period ending 2016-03-31). The top 10 positions account for 78.8% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $1.70B | 17.96% | +20.7% |
| 2 | SGENEURSeattle Genetics, Inc. | $1.52B | 16.00% | +15.9% |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | $910.86M | 9.61% | - |
| 4 | ABBVAbbVie Inc. | $821.02M | 8.66% | - |
| 5 | ACADACADIA Pharmaceuticals Inc. | $677.02M | 7.14% | +18.2% |
| 6 | Incyte Corporation Notes 1.25% 11/15/2020 144A | $432.15M | 4.56% | - |
| 7 | Incyte Corporation Notes 0.375% 11/15/2018 144A | $397.94M | 4.20% | - |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $396.44M | 4.18% | +16.8% |
| 9 | GHDXGenomic Health, Inc. | $338.35M | 3.57% | +0.0% |
| 10 | Anacor Pharmaceuticals, Inc. | $273.79M | 2.89% | +22.0% |
| Stock | Value | Shares |
|---|---|---|
| XNPT 2.5 02/01/22Xenoport, Inc. Notes 2.5% 2/1/2022 | $73.44M | 100,000,000 |
| ONCBeiGene, Ltd. | $56.06M | 1,912,680 |
| EXELExelixis, Inc. | $10.32M | 2,580,000 |
| ARWRArrowhead Pharmaceuticals, Inc. | $4.87M | 1,009,509 |
| InVivo Therapeutics Holdings Corp. | $2.79M | 400,000 |
| ADMSEURAdamas Pharmaceuticals, Inc. | $2.50M | 172,630 |
| GWPHGW Pharmaceuticals plc | $1.08M | 15,000 |
| Discovery Laboratories, Inc. | $426.00K | 254,973 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.